MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why SPTX Stock surged +3.53% Today — RQD Quant Desk Flash
$21.10 +3.53% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $21.19
Seaport Therapeutics Inc. (SPTX) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $1.13B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $21.19 (+0.45%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.8% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-0.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SPTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (56/100 Composite)
🔍 WHY SPTX SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (23% of score)
FRED Regime × Technicals: 46% of 52W Range • RSI-14 at 48.7 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$18.15-1.8% Next Q
48
Q2 (-2Q)Grade C-$17.83+15.6% Next Q
51
Q3 (-1Q)Grade C-$20.61+2.4% Next Q
53
CurrentGrade D+$21.10-0.4% Hist 90D α
56
Trajectory: D (48) → D+ (56)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the SPTX Bull Thesis Could Fail
Even with a 56/100 (D+) score, SPTX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($21.16) or 200D SMA ($20.13) invalidates the momentum regime and cuts Target Base ($20.91) toward Bear Floor ($16.31).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SPTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SPTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SPTX Stock surged +3.53% Today — RQD Quant Desk Flash
Seaport Therapeutics Inc. (SPTX) surged +3.53% to $21.10, trading at 46% of its 52-week range ($14.85 – $28.38). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 46% of its 52-week range ($14.85 – $28.38) with RSI-14 at 48.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $21.10 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $31.6M annual free cash flow.
Live SPTX Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SPTX)
- ✓Walkthrough of SPTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SPTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +6.35%📐 HORIZONTAL RANGE
2026-10-30O $20.96H $21.16L $19.00C $21.10VOL 549.2K
RES: $34.31SUP: $15.03SMA50: $21.16SMA200: $20.13
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SPTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SPTX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SPTX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SPTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SPTX)
Health Care Rank #265 of 1016
⚔️ MNKD vs SPTX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SPTX vs. MNKD, HROW, AVLN, CTY)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Seaport Therapeutics Inc. (SPTX) ranks #265 by composite RQD confidence (56/100, grade D+) and #346 by equity capitalization ($1.13B). Within this direct 5-issuer industry benchmark cohort, SPTX leads on earnings valuation at N/A trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. HROW currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with SPTX at 56/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SPTX
ACTIVE
Seaport Therapeutics Inc. | D+ | 56/100 | — | — | — | +3.53% | $1.13B | Benchmark Subject |
| MNKD MannKind Corporation | C | 63/100 | — | 92.3% | 54.5% | +2.04% | $1.13B | /mnkd-vs-sptx → |
| HROW Harrow Inc. | B- | 71/100 | — | 75.1% | 42.9% | +2.04% | $1.12B | /hrow-vs-sptx → |
| AVLN Avalyn Pharma Inc. | D | 49/100 | — | — | — | -0.12% | $1.14B | /avln-vs-sptx → |
| CTY City Therapeutics Inc. | C- | 61/100 | — | — | — | +2.26% | $1.11B | /cty-vs-sptx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002042347In its most recent audited fiscal period (FY2025, filed 2025-12-31), Seaport Therapeutics Inc. (SPTX) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, SPTX closed FY2025 with $249.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $249.0M | — |
3. SPTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SPTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Seaport Therapeutics Inc. (NASDAQ: SPTX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $21.10 (+3.53% 1D, market cap $1.13B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SPTX ranks #265 in composite RQD confidence.
How does SPTX compare to MNKD and HROW in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPTX carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MNKD (MannKind Corporation) holds a C grade (63/100 RQD, P/E N/A, ROIC 54.5%, cap $1.13B) and HROW (Harrow Inc.) posts a B- grade (71/100 RQD, P/E N/A, ROIC 42.9%, cap $1.12B). Among the 5-stock peer group, SPTX leads on earnings multiple (N/A) while MNKD leads on capital efficiency (54.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SPTX?
Per SPTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002042347), Seaport Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $249.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SPTX trading relative to its 50-day, 200-day, and 52-week technical levels?
SPTX last traded at $21.10 (+3.53% on volume of 272,154 shares), positioning the stock -0.28% below its 50-day simple moving average ($21.16) and +4.82% above its 200-day simple moving average ($20.13). Across its 52-week range of $14.85 to $28.38, SPTX sits at the 46.2% percentile with a 14-day RSI of 48.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($18.46 to $23.74).
SPTX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SPTX stock moving today?
Why SPTX Stock surged +3.53% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.